Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG (pH4, 10%) for primary immune thrombocytopenia
CTR20200030Phase 3Completed
- Sponsor
- Chengdu Rongsheng Pharmaceutical
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Human normal immunoglobulin G in immune thrombocytopenia (ITP), sponsored by Chengdu Rongsheng Pharmaceutical. Started Feb 2020; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20200030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200030.